drugset / Trial / NCT03950687
Study of rESP Injection for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis
RandomizedParallel-groupOpen-labelTreatment
Summary
A phase 2, randomized, open label, active comparator parallel controlled study to explore the dosage regiment of rESP, and evaluate its efficacy, safety and pharmacokinetic characteristics in the treatment of anemia in chronic renal failure patients with hemodialysis
Timeline
- Start
- 2019-06-24
- Primary completion
- 2020-06-30
- Completion
- 2020-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | epoetin alfa | Protein / enzyme biologic | — | Intravenous |
| Subject | rESP | Protein / enzyme biologic | 0.5 ug/kg | Intravenous |
| Subject | rESP | Protein / enzyme biologic | 1 ug/kg | Intravenous |